Anavex Life Sciences to Showcase at BTIG Virtual Biotechnology Conference 2023

(GLOBE NEWSWIRE) — NEW YORK, Aug. 2, 2023 — Anavex Life Sciences Corp. (“Anavex” or “the Company”) AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders like Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system (CNS) disorders, announced today that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will take part in a fireside chat at the B.

The chat will happen on August 7, 2023, at 12:30 p.m. Eastern Time (ET). The BTIG Virtual Biotechnology Conference platform will also let you watch it again.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. AVXL is a publicly traded biopharmaceutical company that focuses on making new medicines to treat Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other diseases of the central nervous system (CNS), as well as pain and different types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully finished a Phase 2a and recently a Phase 2b/3 clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is a drug candidate that can be taken by mouth. It targets sigma-1 and muscarinic receptors to restore balance in cells. Studies before it was used on people showed that it could stop or even cure the effects of Alzheimer’s disease. In animal models, ANAVEX®2-73 also had properties that made it anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant. This suggests that it could be used to treat other CNS diseases, such as epilepsy. The Michael J. Fox Foundation for Parkinson’s Research gave Anavex a research grant that paid for a preclinical study to develop ANAVEX®2-73 as a drug for Parkinson’s disease. ANAVEX®3-71, which works on sigma-1 and M1 muscarinic receptors, is a potential drug candidate in the clinical stage. In transgenic (3xTg-AD) mice, it showed disease-modifying activity against the main symptoms of Alzheimer’s disease, such as cognitive deficits, amyloid pathologies, and tau pathologies. In tests that didn’t involve people, ANAVEX®3-71 helped with mitochondrial malfunction and neuroinflammation. You can find more details at You can also find the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements 

Forward-looking statements are the parts of this news release that are not strictly about the past. These statements are just guesses based on what we know now and what we expect to happen. There are a lot of risks and unknowns involved. Actual events or results may be very different from what is said in any of these statements. This can be caused by a number of things, such as the risks listed in the Company’s most recent Annual Report on Form 10-K that was filed with the SEC. Readers are warned not to put too much stock in these comments about the future, which only apply as of the date of this report. All forward-looking statements are qualified by this warning, and Anavex Life Sciences Corp. is not required to change or update this press release to reflect events or changes that happen after the date of this release.

Follow Instagram, Youtube, Twitter

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939



Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top